Rutugandha Paranjpe1, Grace John2, Meghana Trivedi3,4, Susan Abughosh5. 1. Departments of Pharmaceutical Health Outcomes and Policy, University of Houston, College of Pharmacy, 4849 Calhoun Road, Houston, TX, 77204-5047, USA. 2. University of Houston, College of Pharmacy, 4849 Calhoun Road, Houston, TX, 77204-5047, USA. 3. Pharmacy Practice and Translational Research, University of Houston, College of Pharmacy, 4849 Calhoun Road, Houston, TX, 77204-5047, USA. 4. Pharmacological and Pharmaceutical Sciences, University of Houston, College of Pharmacy, 4849 Calhoun Road, Houston, TX, 77204-5047, USA. 5. Departments of Pharmaceutical Health Outcomes and Policy, University of Houston, College of Pharmacy, 4849 Calhoun Road, Houston, TX, 77204-5047, USA. smabughosh@uh.edu.
Abstract
PURPOSE: Approximately 70-80% of breast cancers are hormone receptor-positive (HR+). OET, including tamoxifen and aromatase inhibitors, is considered standard adjuvant therapy for HR+ breast cancer. Despite demonstrated benefits, nearly half of patients are non-adherent and over two-thirds discontinue therapy before the recommended 5 years. Our objective was to identify and summarize literature-reported barriers associated with non-adherence/non-persistence to OET among breast cancer survivors. METHODS: A PUBMED literature search was conducted using the following terms: 'breast cancer,' 'oral endocrine therapy' or 'Tamoxifen' or 'Aromatase Inhibitors,' 'adherence,' or 'barriers.' The search was restricted to past six years. The abstracts of each result were reviewed and categorized as either patient-reported or physician-reported. All patient- and physician-reported factors that affected adherence and persistence were listed and grouped together into the three main categories: Socio-demographic and medical parameters, general psychosocial parameters, and psychosocial parameters related to OET. RESULTS: A total of 320 articles were identified, of which 19 met inclusion criteria. Adverse drug reactions were the most commonly reported barrier but were generally underreported among physicians. Among patient-reported barriers, common social-demographic and medical parameters were age, comorbidity, and financial status. General psychosocial variables were lack of patient-provider communication, depressive symptoms, and lack of perceived self-efficacy. Treatment toxicity was the most commonly reported psychosocial parameter related to OET. CONCLUSION: The determinants of non-adherence and non-persistence are multi-dimensional and influenced by several factors. The three categories of adherence barriers should be evaluated and considered when designing future interventions to enhance OET adherence for a tailored approach.
PURPOSE: Approximately 70-80% of breast cancers are hormone receptor-positive (HR+). OET, including tamoxifen and aromatase inhibitors, is considered standard adjuvant therapy for HR+ breast cancer. Despite demonstrated benefits, nearly half of patients are non-adherent and over two-thirds discontinue therapy before the recommended 5 years. Our objective was to identify and summarize literature-reported barriers associated with non-adherence/non-persistence to OET among breast cancer survivors. METHODS: A PUBMED literature search was conducted using the following terms: 'breast cancer,' 'oral endocrine therapy' or 'Tamoxifen' or 'Aromatase Inhibitors,' 'adherence,' or 'barriers.' The search was restricted to past six years. The abstracts of each result were reviewed and categorized as either patient-reported or physician-reported. All patient- and physician-reported factors that affected adherence and persistence were listed and grouped together into the three main categories: Socio-demographic and medical parameters, general psychosocial parameters, and psychosocial parameters related to OET. RESULTS: A total of 320 articles were identified, of which 19 met inclusion criteria. Adverse drug reactions were the most commonly reported barrier but were generally underreported among physicians. Among patient-reported barriers, common social-demographic and medical parameters were age, comorbidity, and financial status. General psychosocial variables were lack of patient-provider communication, depressive symptoms, and lack of perceived self-efficacy. Treatment toxicity was the most commonly reported psychosocial parameter related to OET. CONCLUSION: The determinants of non-adherence and non-persistence are multi-dimensional and influenced by several factors. The three categories of adherence barriers should be evaluated and considered when designing future interventions to enhance OET adherence for a tailored approach.
Entities:
Keywords:
Adherence; Barriers; Breast cancer; Oral endocrine therapy
Authors: M Opdam; V van der Noort; M Kleijn; A Glas; I Mandjes; S Kleiterp; F S Hilbers; D T Kruger; A D Bins; P C de Jong; P P J B M Schiphorst; T van Dalen; B Flameling; R C Rietbroek; A Beeker; S M van den Heiligenberg; S D Bakker; A N M Wymenga; I M Oving; R M Bijlsma; P J van Diest; J B Vermorken; H van Tinteren; S C Linn Journal: Breast Cancer Res Treat Date: 2022-05-19 Impact factor: 4.624
Authors: Marine Solano; Etienne Daguindau; Cyril Faure; Pierre Loriod; Coline Pain; Anne-Cécile Maes; Pauline Marguet; Marie Kroemer; Anne Rumpler; Jean Fontan; Eric Deconinck; Samuel Limat; Anne-Laure Clairet Journal: Ann Hematol Date: 2021-05-03 Impact factor: 3.673
Authors: Miryam Yusufov; Margo Nathan; Aleta Wiley; Julia Russell; Ann Partridge; Hadine Joffe Journal: Breast Cancer Res Treat Date: 2020-09-12 Impact factor: 4.872
Authors: Betina Yanez; Robert J Gray; Joseph A Sparano; Ruth C Carlos; Gelareh Sadigh; Sofia F Garcia; Ilana F Gareen; Timothy J Whelan; George W Sledge; David Cella; Lynne I Wagner Journal: JAMA Oncol Date: 2021-06-17 Impact factor: 33.006
Authors: Kyriakos Souliotis; Lily E Peppou; Marina Economou; Androniki Marioli; Sofia Nikolaidi; Maria Saridi; Dimitrios Varvaras; Antonia Paschali; Konstantinos N Syrigos Journal: Asian Pac J Cancer Prev Date: 2021-06-01